Skip to content

Oscor Permanent Retractable Screw-In Pacing Lead Model PR

by Oscor Medical Corp.

510(k) K964107

Active United States

510(k)

Valid until

No expiry

510(k) clearance is not time-limited

FDA recalls

None found

in data synced 22 Oct 2026

Documents

Trust

Unverified

Registry data, not yet checked by deviCERTS. Source FDA 510(k), synced 22 Oct 2026. What this means

Regulatory status

as of registry sync 22 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesFDA 510(k)PT Traditional NumberK964107 Date1 Apr 1997DecidedStatusActive

Recalls

0 recalls · FDA

No FDA recalls found in the data synced 22 Oct 2026.

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — FDA 510(k) Active

Specification

510(k)

510(k) Number
FDA Product Code
DTB
Device Class
Class III
Regulation
21 CFR Part 870.3680
Advisory Committee
Cardiovascular
FDA Decision
PT

Overview

AI-generated summary, 18 Sep 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

The Oscor Permanent Retractable Screw-In Pacing Lead Model PR is a Permanent Pacemaker Electrode, designed for transvenous implantation in the heart to deliver electrical pacing therapy. This device features a retractable design with screw-in fixation, ensuring stable lead positioning within the cardiac chamber for reliable pacing stimulation.

This lead is intended for use in cardiac electrophysiology procedures, supplied sterile and intended for single-use. It is classified as a Class III medical device under FDA regulations and requires compliance with 21 CFR 870.3680. The Model PR is available in specific configurations as referenced in the registration numbers, with no noted MRI compatibility restrictions. Storage and handling must adhere to sterile medical device protocols.

Other devices from Oscor Medical Corp.

See all devices from Oscor Medical Corp. →

Questions

AI-generated answers, 18 Sep 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

  • What is the primary purpose of the Oscor Permanent Retractable Screw-In Pacing Lead Model PR and how is it implanted?

    The Oscor Permanent Retractable Screw-In Pacing Lead Model PR is designed for transvenous implantation in the heart to deliver reliable electrical pacing therapy. Its retractable screw-in fixation mechanism ensures stable positioning within the cardiac chamber, which is critical for consistent pacing stimulation during cardiac electrophysiology procedures.

  • Is this device intended for single-use or can it be reused after sterilization?

    The Oscor Permanent Retractable Screw-In Pacing Lead Model PR is explicitly supplied sterile and intended for single-use only. Reuse is not recommended or supported by the manufacturer, as it could compromise sterility and device integrity.

  • What storage and handling precautions should be taken for this device?

    Since the lead is sterile and single-use, it must be stored and handled according to standard sterile medical device protocols. This includes maintaining the packaging integrity until immediate use and adhering to manufacturer guidelines to prevent contamination or damage.

  • Are there any known restrictions on using this device in patients who require MRI scans?

    The Oscor Permanent Retractable Screw-In Pacing Lead Model PR does not have any explicitly stated MRI compatibility restrictions in the provided data. However, MRI use with pacing leads generally requires careful consideration due to potential electromagnetic interference risks, so clinical judgment and institutional protocols should guide its application.

  • How is this device regulated by the FDA, and what classification does it fall under?

    The Oscor Permanent Retractable Screw-In Pacing Lead Model PR is classified as a Class III medical device under FDA regulations and is subject to compliance with 21 CFR 870.3680. It was cleared via a 510(k) submission (Traditional pathway) and falls under the Cardiovascular (CV) Advisory Committee, with a decision of Substantially Equivalent and tracking requirements.